TREATMENT OF LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA WITH SEVERE COMORBIDITIES: A CASE REPORT

Advanced cutaneous squamous cell carcinoma (aCSCC) presents a significant therapeutic challenge, especially in patients with severe comorbidities that limit treatment options. Traditional treatments such as surgery and radiation may be unfeasible in frail patients, necessitating alternative therapies like immunotherapy. We present the case of a 79-year-old male with a history of recurrent aCSCC, complicated by multiple severe comorbidities, including coronary artery disease, heart failure, chronic kidney disease, and hypothyroidism. After the development of facial nerve palsy and confirmation of metastatic disease, he was treated with cemiplimab, a PD-1 inhibitor, through an Early Access Program. Despite his complex medical status and fluctuating performance status (ECOG 2-3), the patient showed partial reduction in tumor size and improved quality of life, with no significant adverse effects. This case highlights the potential of cemiplimab as an effective therapeutic option for patients with aCSCC who are ineligible for conventional treatments due to comorbidities, offering an alternative approach to managing this challenging condition.

Authors

Publication Details

Journal
Sveikatos mokslai
Published
2026-11-16
DOI
https://doi.org/10.35988/sm-hs.2026.288
Primary Topic
Nonmelanoma Skin Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

TREATMENT OF LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA WITH SEVERE COMORBIDITIES: A CASE REPORT

Donatas Petroška, Vincas Urbonas, Ignas Lapeikis, Ieva Armonaitė et al.
4 links
Sveikatos mokslai
Nonmelanoma Skin Cancer Studies
article

TREATMENT OF LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA WITH SEVERE COMORBIDITIES: A CASE REPORT

Donatas Petroška, Vincas Urbonas, Ignas Lapeikis, Ieva Armonaitė, Ugnius Mickys
article en

Abstract

Advanced cutaneous squamous cell carcinoma (aCSCC) presents a significant therapeutic challenge, especially in patients with severe comorbidities that limit treatment options. Traditional treatments such as surgery and radiation may be unfeasible in frail patients, necessitating alternative therapies like immunotherapy. We present the case of a 79-year-old male with a history of recurrent aCSCC, complicated by multiple severe comorbidities, including coronary artery disease, heart failure, chronic kidney disease, and hypothyroidism. After the development of facial nerve palsy and confirmation of metastatic disease, he was treated with cemiplimab, a PD-1 inhibitor, through an Early Access Program. Despite his complex medical status and fluctuating performance status (ECOG 2-3), the patient showed partial reduction in tumor size and improved quality of life, with no significant adverse effects. This case highlights the potential of cemiplimab as an effective therapeutic option for patients with aCSCC who are ineligible for conventional treatments due to comorbidities, offering an alternative approach to managing this challenging condition.

Sveikatos mokslai
Good health and well-being
Nonmelanoma Skin Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon